Monthly Archives: July 2009

House Energy and Commerce Committee Vote Marks Another Step Forward on Pathway to Biosimilars

House Energy and Commerce Committee Vote Marks Another Step Forward on Pathway to Biosimilars Strong bipartisan support for inclusion of pathway in health care reform legislation Washington, D.C. (July 31, 2009) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the approval of an amendment to create a regulatory pathway for biosimilars by the House Energy and Commerce Committee in today’s mark-up of the America’s Affordable Health Choices Act Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags:

Technology Transfer Symposium at BIO Investor Forum

   Technology Transfer Symposium: Promoting Public-Private Collaboration for Innovation Wednesday October 28, 2009 7:30 am – 12 pm PT The Palace Hotel San Francisco, CA The Technology Transfer Symposium, held in conjunction with the BIO Investor Forum, will explore the domestic and international policy challenges for professionals in university, industry, and legal areas regarding the administration of technology transfer.  This groundbreaking meeting will bring together stakeholder groups to discuss the challenges and opportunities of today’s Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

Clearing Another Hurdle on the Pathway to Biosimilars

The House Energy and Commerce Committee, by a vote of 47 to 11, overwhelmingly adopted an amendment creating a regulatory pathway for biosimilars that will provide 12 years of data exclusivity for innovative biologics. The strong bipartisan support for this amendment to the America’s Affordable Health Choices Act marks the second win this month for a fair and balanced approach to biosimilars market entry. This vote was a clear victory for patients. The ALS Association Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Terminating the Myth—Setting the Record Straight

I was scrolling through a list of blogs that mention genetically modified (GM) foods when a post caught my eye. The post was on a blog called, “Jesus Lives,” and the author of the post, “Prophecy News Watch.” I’m always pleased to see groups discussing GM foods, however I think it’s important to get the facts right, particularly when I came to the following paragraph, “There are other issues — the question of the introduction Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

New Series: Biotechnology Companies at Forefront of Global Health Innovation – Post #1: GlaxoSmithKline & Alnylam Pharmaceuticals

On July 8 2009, GlaxoSmithKline (GSK) and Alnylam Pharmaceuticals, Inc. announced a patent pool to compile intellectual property (IP) to develop treatments for 16 tropical diseases as identified by the FDA including malaria, TB and Chagas, found in 49 Least Developed Countries as defined by the United Nations.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,